Details for New Drug Application (NDA): 217171
✉ Email this page to a colleague
The generic ingredient in SYFOVRE is pegcetacoplan. One supplier is listed for this compound. Additional details are available on the pegcetacoplan profile page.
Summary for 217171
Tradename: | SYFOVRE |
Applicant: | Apellis Pharms |
Ingredient: | pegcetacoplan |
Patents: | 11 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217171
Generic Entry Date for 217171*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVITREAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 217171
Mechanism of Action | Complement Inhibitors |
Suppliers and Packaging for NDA: 217171
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171 | NDA | Apellis Pharmaceuticals, Inc. | 73606-020 | 73606-020-01 | 1 VIAL, GLASS in 1 CARTON (73606-020-01) / 3 mL in 1 VIAL, GLASS |
SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171 | NDA | Apellis Pharmaceuticals, Inc. | 73606-020 | 73606-020-11 | 1 VIAL, GLASS in 1 CARTON (73606-020-11) / 3 mL in 1 VIAL, GLASS |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVITREAL | Strength | 15MG/0.1ML (15MG/0.1ML) | ||||
Approval Date: | Feb 17, 2023 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | May 14, 2026 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Regulatory Exclusivity Expiration: | Feb 22, 2026 | ||||||||
Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
Patent: | 10,035,822 | Patent Expiration: | Nov 15, 2033 | Product Flag? | Substance Flag? | Y | Delist Request? |
Complete Access Available with Subscription